INTERBRI · CHINA MARKET ACCESS FOR MEDICAL DEVICES China-focused support. Clear scope. Accountable coordination.
Regulatory Analysis

China Medical Device Market Access: A Practical Roadmap

10 min readMarket access & compliance

China is among the largest medical device markets in the world, and for most overseas manufacturers it remains an under-penetrated opportunity — but market entry succeeds only when the regulatory track and the commercial track are built in the right order. This article lays out the full picture of China medical device market entry: what the law requires before any unit can be sold, who should hold which role, how import and distribution compliance works, and a step-by-step roadmap from first assessment to first shipment.

1. The non-negotiable starting point: no registration, no import

Chinese law is unambiguous: imported devices must be devices that have been registered or filed under the regulations (Decree No. 739, Article 57). Every imported unit must carry Chinese labels and Chinese instructions for use, including the name, address and contact details of the China-domiciled entity designated by the manufacturer; products without compliant Chinese labeling may not be imported (Article 57). Port inspection authorities verify conformity for imported devices (Article 58). In short: regulatory clearance comes first — channel building without a registration certificate creates risk for everyone in the chain.

2. The regulatory track: class decides everything

Your product’s risk class determines the pathway and the clock: imported Class I devices are record-filed with the NMPA (fast, document-based), while imported Class II and III devices are registered with the NMPA through technical review — 60/90 statutory working days for the review stage, plus preparation, testing and clinical evaluation ahead of it. We walk the full registration sequence in our registration guide; the strategic points for market entry are:

  • confirm classification before committing resources — catalogue adjustments can move a product between filing and registration;
  • the registration certificate is held by you (the overseas manufacturer), with a China legal agent acting as your regulatory counterpart — you stay in control of your license;
  • budget realistically: testing, clinical evaluation and review cycles make registration a quarters-to-years project, not a paperwork exercise.

3. The role map: agent, distributor, importer — keep them distinct

Three roles recur in every China entry plan, and mixing them is the most common design error:

Table: 3. The role map: agent, distributor, importer — keep them distinct
RoleWhat it isCan you have more than one?
China legal agentMandatory regulatory counterpart designated by you (overseas registrant/filer); handles NMPA submissions, vigilance and recall support; appears on Chinese labelsOne designation per registration; independent from sales keeps your license insulated from commercial changes
DistributorCommercial partner who buys/resells; Class II device operation needs filing and Class III needs a license (Decree 739, Arts. 41–42)Yes — many manufacturers appoint several regional distributors
Importer of recordEntity that clears the goods; must keep incoming inspection records and traceability (Art. 45)Usually your distributor or a trading affiliate

Registering the product under your own name with an independent agent, then appointing distributors commercially, gives you the strongest position: your certificate does not belong to any channel partner, and changing distributors never touches the registration.

4. Distribution and import compliance

After clearance, the commercial chain has its own obligations: distributors of Class II devices file with the municipal regulator and Class III distributors need a distribution license (Articles 41–42); incoming inspection and sales records must be traceable (Article 45); labels and IFUs travel with every unit; and advertising for medical devices requires prior content review and an approval number before publication (Article 60). None of this is heavy for a prepared company — but it must be designed into distributor agreements, not discovered after launch.

5. Accelerated and special pathways

Several statutory pathways can compress timelines for qualifying products: the innovative device program for products with core Chinese patents and first-in-class mechanisms (Order No. 47, Articles 68–72), the priority program for rare-disease, oncology, pediatric and clinically urgent devices (Articles 73–75), conditional approval for urgently needed devices (Decree No. 739, Article 19), and the emergency procedure for public-health needs (Order No. 47, Articles 76–78). Eligibility is specific; a regulatory assessment will tell you whether any apply to your portfolio.

6. Post-market: the duties that keep you in the market

Market entry is a commitment to operate, not just to register: adverse event monitoring and reporting (deaths within 7 days, serious injuries within 20 days of awareness), recall readiness, UDI submission per rollout batches, periodic risk evaluation reports, change management and renewal six months before the 5-year certificate expiry. Overseas holders carry these duties in full, implemented with the China legal agent’s support — see our post-market Q&A for the working details.

7. A ten-step roadmap for overseas manufacturers

  1. Define the product scope and intended use you want to register in China;
  2. Confirm classification against the catalogue; request a determination where unclear;
  3. Run a gap assessment: evidence, testing, clinical route, labeling, home-market approvals;
  4. Appoint an independent China legal agent and sign a robust agreement;
  5. Build the submission plan with realistic dates and budget;
  6. Prepare the dossier in Chinese; arrange notarization/legalization of overseas documents;
  7. Complete testing (or self-testing) and the clinical evaluation route;
  8. Submit, manage deficiency responses within the statutory windows, and obtain the certificate;
  9. Set up distribution: qualified distributors, import chain, compliant Chinese labels;
  10. Operate post-market: vigilance, UDI, changes, renewal planning — from day one.
This roadmap summarizes Decree No. 739 and Order No. 47 at a strategic level. Each product’s pathway depends on its class, evidence and market history — validate the plan against current official requirements. INTERBRI builds and runs China entry plans for overseas manufacturers end to end.
Back to the Regulation Library